At a glance
ClinicalIndex Comparison Record- ✓Impaired glucose tolerance
- ✕Diagnosis of diabetes
- ✕Taking an ACE inhibitor (ACE-I), angiotensin II receptor blocker (ARB), or aspirin
- ✕Systolic blood pressure >140 mm Hg
- ✕Chronic inflammatory disorder (rheumatoid arthritis, inflammatory bowel disease, sinusitis)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CVD Risk and Prevention in Early Glucose Intolerance
In Brief
A clinical study evaluating Aspirin, Alpha lipoic acid, and 2 other interventions for Impaired Glucose Tolerance and Prediabetic State. Completed, enrolled 84 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
Study Details
Timeline
Interventions
325 mg PO QD
600 mg PO BID
40 mg PO QD
Identical placebo for each active comparator: placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD